BGMS
NASDAQ · Biotechnology
Bio Green Med Solution Inc
$1.05
+0.05 (+5.00%)
BGMS News26 articles
HCW Biologics Surges 262% on Trimmune Deal and Profit, Nasdaq Risk Looms
HCW Biologics shares jumped 262% after a licensing deal with Beijing Trimmune Biotech fueled a Q1 profit. The company still faces Nasdaq delisting risks and will seek shareholder approval for a reverse stock split.
Biogen Completes Apellis Takeover, Gains Rare-Disease Pipeline
Biogen has completed its acquisition of Apellis Pharmaceuticals, delisting APLS shares. Biogen gains Syfovre and Empaveli, plus a kidney disease pipeline, with a CVR tied to Syfovre sales.
HCW Biologics Posts Profit on China Deal, Faces Nasdaq and Pipeline Tests
HCW Biologics posted a $3.47M profit in Q1 2026, driven by a licensing deal with Trimmune Biotech. The company still trades below Nasdaq's $1 minimum and awaits early human data for its lead alopecia drug.
REGENXBIO Shares Tumble 37% Despite Duchenne Gene Therapy Trial Success
REGENXBIO (RGNX) stock plummeted 37% to $6.31 despite positive Phase III data for RGX-202, as two serious adverse events and FDA approval doubts overshadowed the results.
Biogen Completes Apellis Takeover, Ending Nasdaq Listing
Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing.
Work Medical Stock Skyrockets 206% on AI BioToken Pact, Then Plunges
WORK Medical Technology Group shares tripled on an AI partnership with Shanghai Novabioplus, then plunged 48% in premarket. The deal targets protein modeling and BioTokens but lacks financial details.
Cellectar Biosciences Secures $140M, Pushes Iopofosine Toward FDA Filing
Cellectar Biosciences secured up to $140 million in new funding and reported strong Phase 2b results for iopofosine, fueling plans for a confirmatory trial and FDA filing in Waldenström macroglobulinemia.
Lunai Bioworks Patent Deal Boosts Nasdaq Compliance Bid
Lunai Bioworks completed a $20 million patent acquisition via preferred stock, bolstering its Nasdaq listing compliance. Shares remain under $1.
Cabaletta Bio Surges 32% on Early Cell Therapy Data and $150M Financing
Cabaletta Bio shares surged 32% on early cell therapy data and a $150M stock offering. Two of four patients showed clinical activity with rese-cel.
Cue Biopharma Rockets 91% on Allergy Drug License, CEO Change, and $30M Capital Raise
Cue Biopharma shares soared 91.4% after licensing Ascendant-221, a Phase 2 anti-IgE antibody, naming Shao-Lee Lin as CEO, and raising $30 million.
Biogen Lowers 2026 Profit View Despite Q1 Beat; Leqembi Sales Soar 74%
Biogen lowered its 2026 adjusted earnings outlook to $14.25-$15.25 per share after Q1 results topped estimates. Leqembi sales jumped 74% to $168M globally.
Zimmer Biomet Stock Falls 9% Despite Earnings Beat and Raised Forecast
Zimmer Biomet shares dropped 9% Tuesday after beating Q1 estimates and raising its 2026 profit forecast, as investors focused on an unchanged sales outlook and the CFO's exit.
Edesa Biotech Surges 54% on Renewed ARDS Drug Optimism
Edesa Biotech (EDSA) shares surged 54% on Monday, driven by renewed interest in February data showing paridiprubart reduced 28-day ARDS mortality to 24% from 33%.
Sagimet Biosciences Soars After $175M Stock Sale to Fund Acne Drug Trial
Sagimet Biosciences shares surged 38% after announcing a $175 million stock offering to fund a Phase 3 acne trial for denifanstat, with proceeds expected to support dermatology programs through 2028.
Psyence Biomedical Stock Surges on White House Psychedelic Research Push
Psyence Biomedical's stock rose sharply following a White House executive order aimed at fast-tracking research into psychedelic therapies like ibogaine, though the company's lead drug remains in mid-stage trials.
Biogen Acquires Apellis in $5.6B Deal, Adding Eye and Kidney Drugs
Biogen has entered a definitive agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion. The deal includes a $41 per share cash offer plus contingent value rights.
Biogen to Acquire Apellis in $5.6B Deal, Adding Rare Disease Portfolio
Biogen has entered an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash. The deal provides Apellis shareholders $41 per share upfront, with potential additional payments based on sales performance of the eye drug Syfovre.
ImmunityBio Plunges 21% on FDA Warning Over Anktiva Marketing
ImmunityBio shares tumbled 21.1% following an FDA warning letter alleging false or misleading promotional claims about its cancer therapy Anktiva. The drug generated essentially all of the company's $113 million in 2025 revenue.
ImmunityBio Surges on NK-Cell Manufacturing Milestone, Anktiva Expansion Progress
ImmunityBio shares jumped 10.5% Friday following news of a completed scalable manufacturing process for its NK-cell therapy platform and regulatory progress for its drug Anktiva. The company also reported surging 2025 revenue.
Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.
Servier Acquires Day One Biopharmaceuticals in $2.5 Billion Oncology Deal
French pharmaceutical firm Servier will acquire Day One Biopharmaceuticals for $2.5 billion, gaining the pediatric glioma treatment Ojemda. The deal offers a 68% premium to Day One's recent closing price.
ImmunityBio Shares Dip Ahead of Key Business Update Call
ImmunityBio shares edged lower in premarket activity Tuesday, giving back some of the prior session's gains ahead of a scheduled business update and full-year results call later in the day.
BioCryst Shares Slip on New Hereditary Angioedema Drug Data
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.
ImmunityBio Shares Stabilize After 15% Surge, Focus Turns to Upcoming Earnings
ImmunityBio's stock held steady near $7 in premarket trading following a sharp 14.6% rally. Investors are now awaiting the company's quarterly results, due in early March.